Physician profile
Panch Jeyakumar
NPI 1629047964
$11,268.59
in general payments reported to CMS, 2019-2025
35 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $225 · 2021: $1,401 · 2022: $2,096 · 2023: $2,911 · 2024: $2,295 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,907.06 |
| Education | $223.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,137.74 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,583.30 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,178.63 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Mylan Specialty L.P. | $975.90 | 2021-2024 | Yupelri |
| Amgen INC. | $812.88 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $646.13 | 2021-2025 | Dupixent |
| Genzyme Corporation | $492.22 | 2021-2025 | |
| Grifols USA, LLC | $468.09 | 2021-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $250.16 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Janssen Biotech, INC. | $216.53 | 2021-2022 | |
| Gilead Sciences, INC. | $188.26 | 2020-2024 | Veklury |
| Verona Pharma, INC. | $172.32 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $137.82 | 2025 | Yupelri |
| Abbvie INC. | $130.20 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.76 | 2020-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $101.35 | 2024-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Advanced Respiratory, INC | $74.00 | 2020-2021 | |
| Insmed, INC. | $69.42 | 2022-2024 | Arikayce |
| Electromed, INC. | $58.07 | 2025 | Smartvest |
| Genentech USA, INC. | $48.43 | 2021-2023 | Xolair |
| Paratek Pharmaceuticals, INC. | $41.88 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $40.57 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $39.17 | 2023-2024 | Xarelto |
| Allergan, INC. | $22.68 | 2020 | |
| Tactile Systems Technology INC | $22.48 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.66 | 2021 | |
| Pulmonx Corporation | $19.57 | 2022 | |
| Inogen, INC. | $17.80 | 2022 | |
| Pfizer INC. | $17.72 | 2021 | |
| Ambu INC. | $17.58 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.67 | 2021 | |
| Shionogi INC | $15.33 | 2021 | |
| Resmed Corp | $14.04 | 2025 | |
| Philips North America LLC | $13.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panch Jeyakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.